Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Viatris, Inc. stands second among them.

Viatris, Inc. (NASDAQ:VTRS) reported strong Q2 2025 results, generating approximately $79 million in revenue from new products while reaffirming its full-year financial guidance. The company continues to advance its pharmaceutical pipeline, with a focus on innovative therapies in ophthalmology, pain management, and women’s health.

In 2025, Viatris, Inc. (NASDAQ:VTRS) achieved several Phase 3 clinical milestones. MR-141 for presbyopia met all primary and secondary endpoints, providing rapid and sustained improvement in near vision without affecting distance vision, along with a consistent safety profile. MR-142 demonstrated effectiveness in keratorefractive patients under low-contrast conditions. XULANE LO, a low-dose birth control patch, showed strong results across endpoints, positioning it as a potential best-in-class option. Additionally, MR-107A-02, a fast-acting meloxicam, delivered significant benefits for moderate-to-severe acute pain in pivotal trials.

The business also expanded its portfolio with the approval of its first generic iron sucrose injection in the U.S., strengthening its presence in key therapeutic areas.

These developments highlight Viatris, Inc. (NASDAQ:VTRS)’s strategic shift from a traditional generics provider to a specialty pharmaceutical player. By leveraging Phase 3 successes and launching new products, VTRS aims to address unmet medical needs while enhancing long-term growth prospects and reinforcing its base business.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.